New Mexico medical psilocybin program · 7.35.4 NMAC

Where things stand

Created October 22, 2026. Every claim on this page cites the proposed text, the hearing notice, or a department recording.

New Mexico's rule for the medical psilocybin treatment equity fund, 7.35.4 NMAC, is proposed, not in effect. The Department of Health published it on October 20, 2026 with an amendment to the definitions at 7.35.2.7 NMAC, and fixed a rule hearing on both for November 20, 2026. The fund itself is created by the Medical Psilocybin Act, Section 26-2D-11 NMSA 1978, for treatment of qualified patients who meet income requirements set by department rule; this is that rule. It follows a recommendation the Advisory Board voted on September 11, and departs from it in places. This Part of the site holds the proposed text, what it would require of the people it reaches, the recommendation beside it, and the record.

Find your part

I am a patient, or care for one

Who would be eligible, how to apply, what proof of residency and income is accepted, the sessions and travel the fund would pay for, how long eligibility lasts, and how to ask for review.

I would bill the fund

For certifying clinicians, practitioners, healing centers, and producers: other payers first, the rate, what a claim carries, the 180-day deadline, records, audits, holds, and overpayments.

Does it match what the board voted?

The committee's August 18 framework and the board's September 11 vote, item by item beside the proposed text, each cited to the recording.

I want the text

All twenty sections as published October 20, verbatim, each cited to the PDF page, with notes where the text departs from the recommendation.

I am following the process

The chain from the committee's July 21 threshold vote to the November 20 hearing, and every document the site holds.

Where things stand

OPENThe department published the proposed 7.35.4 NMAC, Treatment Equity Fund, on October 20, 2026, with a proposed amendment to the definitions at 7.35.2.7 NMAC and a notice fixing the rule hearing for November 20, 2026, 9:00 AM, in the Harold Runnels Building auditorium in Santa Fe, in person, by video conference, and by telephone. The rule is proposed and not in effect. Written comment must be received by the close of the hearing; the notice carries the video conference code, the telephone number, and the written comment address. The text is on The proposed rule.

OPENThe Advisory Board voted 7-0 on September 11, 2026 to recommend the equity fund framework from the Equity, Access and Cultural Considerations Committee, with three preparatory or integrative sessions for each additional administration session. The proposed 7.35.4.14 (A) allows two. The diagnostic evaluation and the cost of medication, both voted, are not named in the section that lists allowable expenses. Item by item on The board recommendation.

Committee vote

EACC AUG 18

Board vote

SEP 11 · 7-0

Proposed

PUBLISHED OCT 20

Rule hearing

NOV 20 · BY NOTICE

Adopted

NOT YET

Scheduled

NOV 20Rule hearing on the proposed 7.35.4 NMAC and the proposed amendment to 7.35.2.7 NMAC, 9:00 AM, Harold Runnels Building auditorium, Santa Fe, and by video conference and telephone; fixed by the notice published October 20. Written comment is due by the close of the hearing.

Where the text departs from the board vote

.14 (A)Two preparatory or integrative sessions with each later administration; the board voted three. The comparison.

.14 (A)The diagnostic evaluation, voted by both bodies, is not named. The comparison.

.10 (B)Medicaid named among the payers to pursue first, the language the board left to the attorneys. The comparison.

NEWTen provisions the department introduced that neither the committee nor the board took up, among them a 12-month limit on eligibility, a 180-day claim deadline, and no review of a denial made for lack of funds. Each is marked New from the department where it sits. The list.

Every page in this Part

HEREWhere things stand: the state of the rule and the hearing.

TEXTThe proposed rule: all twenty sections, verbatim.

WHOWho the fund would pay, and for what: every requirement, cited.

VOTEThe board recommendation: the vote beside the text.

CHAINMeetings and filings: the dated chain and the register.

Patient enrollment itself is governed by the proposed 7.35.3 NMAC, which has its own pages; the definitions this Part imports sit in 7.35.2 NMAC, on its pages. How this site is built, its sources, and its corrections path are on How this site is built.

Provenance: the source document and this page’s revisions▸

The document this page is read from

October 20, 2026

The proposed rule, 7.35.4 NMACCurrent state of truth

The proposed rule, published by the department on October 20, 2026: twenty sections setting patient eligibility for the medical psilocybin treatment equity fund, the application, reimbursement and claims, allowable expenses and travel, records, audits, payment denial and suspension, overpayments, program monitoring, and administrative review. It is the first published text of this Part, and it is proposed, not in effect; the rule hearing is November 20, 2026.

This document supersedes 0 earlier ones. Each of them, what it is, what superseded it and when, and a download, is in the register at Meetings and filings.

Revisions to this page

October 22, 2026 A line naming the ten provisions the department introduced, linked to the list.
October 22, 2026 Created as the front page of the Part: the plaque, the portals by role, the status surfaces written by tools/sync-status.py, and the page directory.